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ABSTRACT
Germline mutations in the succinate dehydrogenase (SDHA, SDHB, SDHC, 
SDHD, SDHAF2) or Von Hippel-Lindau (VHL) genes cause hereditary paraganglioma/
pheochromocytoma. While SDHB (1p36) and VHL (3p25) are associated with 
autosomal dominant disease, SDHD (11q23) and SDHAF2 (11q13) show a remarkable 
parent-of-origin effect whereby tumor formation is almost completely dependent 
on paternal transmission of the mutant allele. Loss of the entire maternal copy of 
chromosome 11 occurs frequently in SDHD-linked tumors, and has been suggested 
to be the basis for this typical inheritance pattern.
Using fluorescent in situ hybridization, microsatellite marker and SNP array 
analysis, we demonstrate that loss of the entire copy of chromosome 11 is also frequent 
in SDHAF2-related PGLs, occurring in 89% of tumors. Analysis of two imprinted 
differentially methylated regions (DMR) in 11p15, H19-DMR and KvDMR, showed that 
this loss always affected the maternal copy of chromosome 11. Likewise, loss of maternal 
chromosome 11p15 was demonstrated in 85% of SDHD and 75% of VHL-related PGLs/
PCCs. By contrast, both copies of chromosome 11 were found to be retained in 62% 
of SDHB-mutated PGLs/PCCs, while only 31% showed loss of maternal chromosome 
11p15. Genome-wide copy number analysis revealed frequent loss of 1p in SDHB mutant 
tumors and show greater genomic instability compared to SDHD and SDHAF2.
These results show that loss of the entire copy of maternal chromosome 11 is a 
highly specific and statistically significant event in SDHAF2, SDHD and VHL-related 
PGLs/PCCs, but is less significant in SDHB-mutated tumors, suggesting that these 
tumors have a distinct genetic etiology.
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INTRODUCTION
Paragangliomas (PGLs) are neuroendocrine 
tumors derived from cells of the parasympathetic or 
sympathetic ganglia. Parasympathetic PGLs occur most 
commonly in the head and neck region (carotid body, 
glomus jugulare, and glomus typanicum), are typically 
benign, and are rarely associated with catecholamine 
secretion [1, 2]. PGLs arising from the sympathetic 
ganglia occur in the abdomen and thorax, often secrete 
catecholamines, and are associated with a higher risk of 
malignancy. Pheochromocytomas (PCCs) are generally 
benign paragangliomas that arise in the chromaffin cells 
of the adrenal medulla, but are frequently associated with 
hypertension due to excessive catecholamine secretion [3].
Germline mutations in genes encoding subunits 
of succinate dehydrogenase (SDH, complex II of the 
mitochondrial respiratory chain) are the most common 
genetic cause of PGL/PCC, occurring in up to 25% of all 
cases [4, 5]. SDH is a heterotetramer consisting of two 
catalytic subunits, SDHA and SDHB, and two membrane-
spanning subunits, SDHC and SDHD. SDHAF2 encodes 
an accessory factor required for the flavination of SDHA. 
SDH is an essential component of the tricarboxylic acid 
(TCA) cycle and the mitochondrial respiratory chain. A 
puzzling aspect of SDHx-related disease is that despite 
the close functional relationship of the SDH proteins, 
mutations lead to marked differences in both tumor 
location and clinical phenotype.
Another striking difference is that only mutations 
in SDHD and SDHAF2, both located on chromosome 
11, show a parent-of-origin inheritance effect in which 
carriers develop tumors almost exclusively following 
paternal transmission of the mutation [6, 7]. An important 
role in causing this inheritance pattern has been ascribed 
to the loss of the entire maternal copy of chromosome 11 
in SDHD-linked tumors. A cluster of maternally expressed 
imprinted genes is located on chromosome 11p15, 
which formed the basis for a hypothesis now known as 
the ‘Hensen model’. The model proposes that maternal 
chromosomal 11 loss results in the simultaneous deletion 
of the SDHD wild type gene and an as yet unidentified 
exclusively maternally expressed gene (or genes), 
resulting in tumor formation [7]. This hypothesis predicts 
that loss of the maternal copy of chromosome 11 might be 
similarly important for SDHAF2-linked tumors, but has 
yet to be demonstrated.
To further clarify the role of loss of the maternal 
copy of 11p in relation to loss of the long arm of 
chromosome 11 in paragangliomas, we used several 
genetic approaches to determine the allelic status of 
chromosome 11 in SDHAF2, SDHD, SDHB, and VHL 
mutant PGLs/PCCs. SDHB and VHL-related tumors were 
included because these genes map to other chromosomes 
than 11. The results show that tumorigenesis in SDHAF2-
related tumors are fully compatible with the Hensen 
model, and that 11p loss is less important in SDHB-related 
tumors than for the other three tumor subgroups.
RESULTS
Loss of heterozygosity in SDHAF2-related PGL
Since SDHAF2-related PGLs show a parent-
of-origin effect, similar to SDHD mutations [7], we 
hypothesized that their tumorigenesis might also critically 
depend on loss of the maternal copy of chromosome 11. 
We first established SDHAF2 mutation status in germline 
DNA from 9 patients from SDHAF2-related families. 
All patients showed a missense mutation of SDHAF2, 
c.232G>A (p.Gly78Arg), in a conserved region of the 
gene [8]. We then sequenced DNA isolated from tumors of 
all nine patients, and compared this to matched DNA from 
blood samples. This comparison showed that the wild 
type allele (guanine (G) nucleotide – arrow, Figure 1A) 
is underrepresented in tumor DNA (Figure 1B), and the 
mutant allele is (adenine (A) nucleotide) overrepresented, 
indicating loss of the wild type allele (loss of 
heterozygosity - LOH) in the tumor. Partial retention of 
the wild type allele is characteristic of LOH in PGLs, 
and is due to admixture with normal cells that proliferate 
together with tumor cells [9].
Loss of chromosome 11 in SDHAF2-related PGL
To investigate whether the entire copy of 
chromosome 11 is lost in SDHAF2-related tumors, we 
performed fluorescence in situ hybridization (FISH) 
studies on 6 SDHAF2-linked tumors using a probe for 
the centromere of chromosome 1 as a ploidy reference as 
described earlier [7], and BAC probes for the subtelomeric 
regions of 11p and 11q. Simultaneous loss of both probes 
located on chromosome 11 relative to centromere 1 was 
found in all SDHAF2-related PGLs, in 15–44% of nuclei 
(Figure 1C, red and orange). Loss of one of the two probes 
located on chromosome 11 relative to the other was 
observed in only a very small minority of nuclei (< 0.5%), 
demonstrating that the observed relative loss involves the 
entire copy of chromosome 11.
Parental origin of chromosomal loss in SDHAF2-
related PGL
To further evaluate LOH in all SDHAF2-related 
tumors and study the parental origin of chromosomal 
loss, tumor DNA was analyzed for LOH using 24 highly 
polymorphic microsatellite markers selected from a 
custom microsatellite database. In the 9 SDHAF2-related 
PGLs investigated, 8 (89%) showed chromosome 11-
wide LOH, with allelic imbalance ratios of < 0.7 or >1.3 
(Figure 1D, Supplementary Table 2). Parental blood DNA 
samples were available for 3 SDHAF2-related patients. 
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Microsatellite analysis of parental DNA confirmed that 
the copy of chromosome 11 lost in all 3 SDHAF2-mutated 
tumors was maternal (Figure 1E). 
As parental DNA was not available for the remaining 
cases, we investigated the methylation status of two 
11p15.5 DMRs, KvDMR (maternal allele methylated) and 
H19-DMR (paternal allele methylated). In the presence of 
two chromosomes with normal methylation levels, each 
of these DMRs should show an average 50% methylation 
rate (one chromosome methylated, opposite chromosome 
unmethylated). This analysis showed hypermethylation of 
the H19-DMR and hypomethylation in the KvDMR in 8 
(89%) SDHAF2 mutant PGLs (Table 1). These findings 
are consistent with loss of the maternal allele [10]. The 
mean methylation rates (± sd) of 7 SDHAF2-related 
tumors differed significantly from the normal methylation 
rates in matched blood DNA (H19-DMR 0.83 ± 0.13 
versus 0.52 ± 0.03 (p = 0.008) and KvDMR 0.06 ± 0.07 
versus 0.50 ± 0.10 (p = 0.006)). In each of the tumors with 
chromosome 11 loss, the ratio of the methylation rate of 
H19-DMR/KvDMR was > 3, while the ratio of H19-DMR/
KvDMR in blood DNA was ~1. The one SDHAF2-related 
tumor without LOH for chromosome 11 by microsatellite 
marker analysis, demonstrated normal methylation of both 
H19-DMR and KvDMR, comparable to blood DNA. 
Frequent loss of maternal chromosome 11 in 
SDHD and VHL-related tumors
To investigate the extent and nature of chromosome 
11 loss across the various paraganglioma subgroups, we 
assembled a panel of 26 SDHD, 13 SDHB, and 8 VHL-
related PGLs/PCCs. Of the 26 SDHD-related tumors 
investigated using polymorphic microsatellite marker 
analysis, LOH at all informative markers of chromosome 
11 was observed in 22 (85%) tumors (Table 2). In four 
SDHD-related tumors almost all markers showed 
allele ratios between 0.8 and 1, indicating retention of 
heterozygosity (Supplementary Table 3 – tumor 23, 
26, 27 and 36). Methylation analysis of H19-DMR and 
KvDMR demonstrated hypermethylation of H19-DMR 
and hypomethylation of KvDMR in all SDHD mutant 
PGLs with LOH for chromosome 11, consistent with 
loss of the maternal allele and significantly different from 
methylation rates of H19-DMR (p = 0.004) and KvDMR 
(p = 0.002) in blood DNA (Table 2). In the four SDHD-
related tumors without chromosomal loss, the ratio of 
H19-DMR to KvDMR was 1, comparable to blood DNA.
All 8 VHL-associated PCCs demonstrated loss 
of chromosome 11 (Table 3), although in 3 tumors, 
microsatellite markers were uninformative at 11p15 or at 
Figure 1: Sanger sequencing of SDHAF2 in normal (A) and tumor (B) DNA. Arrows indicate the relevant nucleotides in the 
heterozygous patient. (C) Interphase FISH results from isolated whole nuclei isolated from paraffin-embedded material of 6 SDHAF2-related 
patients. Frequency distribution of signals obtained with probes for centromere 1 (PUC1.77), telomere 11p (371C18) and telomere 11q 
(469N6). (D) A typical profile of microsatellite marker alleles showing loss of heterozygosity. Arrows indicate the allele lost. (E) 
Chromosome 11 haplotypes of family members. Microsatellite markers are shown with genomic location and the position of SDHAF2 is 
indicated. Alleles in orange blocks represent the probable disease haplotype, present in the proband and absent in the father. Alleles in blue 
blocks represent alleles from the father.
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11q23, while other markers on chromosome 11 showed 
allelic imbalance ratios of < 0.7 or > 1.3 (Supplementary 
Table 4). 
Methylation status of H19-DMR and KvDMR 
revealed loss of the maternal copy of chromosome 11 
in 6 of 8 (75%) VHL-associated PCCs (Table 3), while 
the methylation status of the H19-DMR could not be 
determined in 2 (25%) tumors. However, both these 
tumors showed hypomethylated KvDMR, suggestive of 
maternal allele loss.
Low frequency maternal chromosome 11 loss in 
SDHB-related tumors
Almost all (92%) SDHB-mutated tumors retained 
heterozygosity in the 11q region, while 4 (31%) tumors 
showed LOH exclusively in the 11p15 region, in 1 
tumor microsatellite markers were uninformative at 
11p15 (Table 4). Moreover, in all cases with LOH, this 
LOH affected multiple small regions of chromosome 11 
alternated with regions of retention of heterozygosity 
(Supplementary Table 5). Methylation analysis of 
H19-DMR and KvDMR in 8 (62%) SDHB mutant 
tumors showed the ratio of H19-DMR to KvDMR was 
~1, comparable to blood DNA. Of the 4 tumors with 
indications for LOH of 11p15, 1 (tumor 51) showed 
hypermethylation of H19-DMR and hypomethylation of 
KvDMR. Tumors 48 and 50 showed hypermethylation of 
H19-DMR but normal methylation of KvDMR, resulting 
in a ratio of H19-DMR/KvDMR < 3 (Table 4). In the 
remaining SDHB mutant tumor (tumor 49), no methylation 
was detected at KvDMR, whereas the methylation rate 
of H19-DMR was normal. These results are in stark 
contrast to the unequivocal findings in SDHAF2, SDHD 
and VHL-related PGLs/PCCs. To investigate whether 
SDHB-mutated tumors show a scattered pattern of LOH 
on other chromosomes, we used microsatellite markers 
from chromosomes known to be affected in PGL/PCC 
[11], including chromosomes 1, 3, 5, 14 and 17. All 
SDHB mutant tumors showed LOH for chromosome 1p, 
presumably affecting the SDHB wild type allele (Figure 2). 
In addition, LOH of other chromosomes, defined as allelic 
imbalance ratios of < 0.7 or > 1.3, was observed in most 
SDHB-related tumors, in contrast to SDHD mutant tumors 
(Figure 2, Supplementary Table 6).
Greater genomic instability in SDHB tumors 
compared to SDHD and SDHAF2-related 
tumors
To further explore genomic instability in these 
tumors, we analyzed genome-wide copy number changes 
and LOH in a total of 28 tumors (12 SDHD, 4 SDHAF2, 
9 SDHB and 3 VHL-related PGLs/PCCs) using SNP array 
analysis. In agreement with our microsatellite marker 
results and with other studies [11–15], the most frequent 
copy number alterations in these tumors were deletions 
of 1p (48%), 3p/q (28%/32%), and 11p/q (88%/68%) 
(Figure 3). Although the SDHB, VHL, SDHD, and 
SDHAF2 genes are located in these chromosomal regions, 
Table 1: Methylation status of 11p15 imprinted regions KvDMR and H19-DMR in SDHAF2 
mutant PGLs with and without chromosome 11 LOH 
Gene mutation 
and sample ID 11p15 status 11q12 status
Methylation rate of 
tumor DNA
H19-DMR/KvDMR 
methylation rate 
Ratio of tumor DNA
Methylation rate of 
matched blood DNA
SDHAF2 (1) LOH LOH (maternal) KvDMR: 0.07
H19-DMR: 0.57
8.1
SDHAF2 (2) LOH LOH KvDMR: 0.01
H19-DMR: 0.94
> 10 KvDMR: 0.59
H19 DMR: 0.52
SDHAF2 (3) LOH LOH KvDMR: 0.001
H19-DMR:0.82
> 10
SDHAF2 (4) LOH n.i KvDMR: 0.03
H19-DMR: 0.97
>10
SDHAF2 (5) LOH LOH (maternal) KvDMR: 0.08
H19-DMR: 0.79
9.8 KvDMR: 0.47
H19 DMR: 0.53
SDHAF2 (6) No LOH No LOH KvDMR: 0.63
H19-DMR: 0.57
0.9 KvDMR: 0.57
H19 DMR: 0.54
SDHAF2 (7) LOH LOH (maternal) KvDMR: 0.22
H19-DMR: 0.81
3.7 KvDMR: 0.37
H19 DMR: 0.47
SDHAF2 (8) LOH LOH KvDMR: 0.03
H19-DMR: 0.9
> 10
SDHAF2 (9) LOH LOH KvDMR: 0.0001
H19-DMR: failed
-
LOH: loss of heterozygosity. n.i : not informative.
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losses occurred independently of the presence of germline 
mutations in these genes (Supplementary Figure 2). SNP 
array analysis revealed patterns of chromosomal gains 
and losses that were more heterogeneous in SDHB mutant 
tumors compared to SDHD and SDHAF2-mutated tumors. 
We evaluated the level of chromosomal instability in each 
tumor by calculating the ‘Fraction of Aberrant Arms’ (i.e. 
the proportion of chromosome arms altered over more 
than 40% of their length [16]). This analysis confirmed 
the greater degree of genome instability in SDHB mutant 
tumors (mean 12%) compared to SDHD mutant tumors 
(mean 4%) or to SDHAF2 mutant tumors (mean 4.5%). 
One SDHD and two SDHB-linked tumors appeared to be 
tetraploid as determined by the 2Log (test/reference) ratios 
Table 2: Methylation status of KvDMR and H19-DMR in SDHD mutant PGLs with and without 
chromosome 11 LOH
Gene mutation 
and sample ID 11p15 status 11q23 status
KvDMR 
methylation rate
H19-DMR 
methylation rate
H19-DMR/KvDMR 
methylation rate. Ratio
SDHD (10) LOH LOH 0.01 0.62 > 10
SDHD (11) LOH LOH 0.0 1.0 > 10
SDHD (12) LOH LOH 0.01 0.96 >10
SDHD (13) LOH LOH 0.10 0.86 8.6
SDHD (14) LOH n.i 0.04 0.97 > 10
SDHD (15) LOH LOH 0.07 1 > 10
SDHD (16) LOH n.i 0.02 0.75 >10
SDHD (17) n.i LOH 0.03 0.45 > 10
SDHD (18) LOH LOH 0.02 0.96 > 10
SDHD (19) LOH n.i 0.0 0.91 > 10
SDHD (20) LOH LOH 0.0 0.87 > 10
SDHD (21) LOH LOH 0.08 0.76 > 10
SDHD (22) LOH n.i 0.14 0.90 6.4
SDHD (23) No LOH No LOH 0.51 0.56 1
SDHD (24) LOH LOH 0.01 0.7 > 10
SDHD (25) LOH LOH 0.04 0.86 > 10
SDHD (26) No LOH No LOH 0.57 0.59 1
SDHD (27) No LOH No LOH 0.53 0.57 1
SDHD (28) LOH LOH 0.17 0.66 3.9
SDHD (29) LOH LOH 0.15 0.68 4.4
SDHD (30) LOH LOH 0.21 0.70 3.3
SDHD (31) LOH LOH 0.16 0.68 4.4
SDHD (32) LOH LOH 0.12 0.71 5.9
SDHD (33) LOH LOH 0.13 0.65 5.2
SDHD (34) LOH LOH 0.11 0.70 6.4
SDHD (35) LOH LOH 0.13 0.69 5.4
SDHD (36) No LOH No LOH 0.48 0.61 1.2
LOH: loss of heterozygosity. n.i : not informative.
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(Supplementary Figure 3). The most commonly affected 
chromosomal regions in SDHB-related tumors were gain 
of 1q (57%), chromosome 7 (28%) and 17q (28%), and 
loss of 1p (100%) (SDHB locus) and 17p (57%). These 
regions have also been shown to be affected in RET, NF1 
and sporadic paragangliomas/pheochromocytomas [11], 
indicating the potential presence of driver genes on these 
autosomes.
DISCUSSION
In this study, we showed that loss of maternal 
chromosome 11 is also a cardinal feature of SDHAF2-
linked paragangliomas. The selective loss of maternal 
chromosome 11 conforms to the Hensen model and 
explains why SDHAF2-linked tumors arise in principal 
upon paternal transmission of the mutation, comparable 
to most SDHD-linked tumors [7, 12, 17]. The presence 
of a paternal parent-of-origin effect in both SDHAF2 and 
SDHD-related PGLs, a phenomenon absent in other SDH-
related PGLs, argues that their location on chromosome 
11 reveals the fundamental role of another chromosome 
11 gene in tumorigenesis. 
The specific loss of maternal chromosome 11 in 
VHL-related PCCs suggests that a maternally-expressed 
gene on chromosome 11 also plays a crucial role in these 
tumors. In this case, no parent-of-origin effect for the 
VHL mutation is predicted because loss of the wild type 
VHL allele on chromosome 3 can occur independently of 
maternal chromosome 11 loss. These findings agree with 
earlier reports [10, 11, 14, 18] showing a high frequency 
of chromosome 11p loss in VHL mutant tumors. It is 
likely that loss of chromosome 11p confers further growth 
advantage to the tumors besides the inactivation of the 
VHL gene. Interestingly, chromosome 11 loss in VHL-
related tumors is specific to PGL/PCC and has not been 
shown in VHL-related renal cell carcinomas [19, 20].
The 11p15 region contains several imprinted genes 
that are exclusively maternally expressed and paternally 
silenced. LOH of maternal chromosome 11 will result in 
complete loss of expression of these genes. Our results 
lend further support to the notion that loss of an as yet 
unidentified locus (or loci) in 11p15 could contribute to 
tumor formation in SDHD, SDHAF2 and VHL-related 
PGLs/PCCs. 
Of the potential candidate genes, the paternally 
expressed growth promoter insulin like growth factor 2 
(IGF2) and the maternally expressed candidate tumor 
suppressor genes CDKN1C and H19, have been most 
consistently implicated in imprinting disorders, such 
as Beckwith-Wiedemann Syndrome and Silver-Russell 
Syndrome [21]. Interestingly, we recently found loss of 
CDKN1C and SLC22A18 expression in SDHD-related 
PGLs compared with normal carotid body tissue and 
established that knockdown of SDHD together with 
SLC22A18 or with CDKN1C led to small increases in cell 
proliferation and resistance to apoptosis in neuronal cells 
[22]. Results from the cell line-based functional assays 
were further supported by the finding that SDHD mutant 
tumors with either retention or loss of chromosome 11 
showed equally low levels of SLC22A18 and CDKN1C 
protein expression [22]. SDHx-related tumors are 
Table 3: Methylation status of KvDMR and H19-DMR in VHL mutant PCCs with and without 
chromosome 11 LOH
Gene mutation 
and sample ID 11p15 status 11q23 status
KvDMR 
methylation rate
H19-DMR 
methylation rate
H19-DMR/KvDMR 
Methylation rate. Ratio
VHL (37) LOH n.i 0 0.65 > 10
VHL (38) LOH LOH 0.01 0.89 > 10
VHL (39) LOH LOH 0.03 0.75 > 10
VHL (40) LOH LOH 0.01 1 > 10
VHL (41) LOH LOH 0.01 1 > 10
VHL (42) LOH LOH 0.01 0.83 > 10
VHL (43) n.i LOH 0.01 failed -
VHL (44) n.i LOH 0 failed -
LOH: loss of heterozygosity. n.i : not informative
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associated with hypermethylation and histone methylation, 
suggesting a possible mechanism underlying the lowered 
expression of SLC22A18 and/or CDKN1C in SDHD 
mutant tumors with retention of chromosome 11. Further 
studies are needed to clarify the role of imprinted genes 
located on 11p15 in tumor development of SDHx and VHL 
mutant PGL/PCC.
While partial or entire loss of chromosome 11 
is a signature event in a proportion of SDHB-related 
tumors, many SDHB tumors exhibit gains and losses 
Figure 2: Frequency (%) plot of loss of heterozygosity (LOH) of different chromosomes in SDHB (black bars) and 
SDHD (grey bars) mutant tumors, determined by microsatellite marker analysis. A higher frequency of LOH of chromosomes 
1, 3, 14, and 17 is observed in SDHB-related tumors compared to SDHD-related tumors. LOH of chromosome 11p is the most frequent 
event in SDHD mutant tumors.
Table 4: Methylation status of KvDMR and H19-DMR in SDHB mutant tumors with and without 
chromosome 11 LOH
Gene mutation 
and sample ID 11p15 status 11q23 status
KvDMR 
methylation 
rate
H19-DMR 
methylation 
rate
H19-DMR/KvDMR 
methylation rate 
Ratio
Methylation rate 
of matched blood 
DNA
SDHB (45) No LOH No LOH 0.39 0.45 1.1 KvDMR: 0.39 
H19: 0.44
SDHB (46) No LOH No LOH 0.68 0.60 0.9
SDHB (47) No LOH No LOH 0.48 0.31 0.6
SDHB (48) LOH No LOH 0.57 0.81 1.4 KvDMR: 0.30 
H19: 0.51
SDHB (49) LOH No LOH 0.09 0.43 4.8 KvDMR: 0.37 
H19: 0.51
SDHB (50) LOH No LOH 0.33 0.91 2.8
SDHB (51) LOH LOH 0.04 0.86 > 10
SDHB (52) n.i No LOH 0.004 0.47 > 10
SDHB (53) No LOH No LOH 0.41 0.69 1.7
SDHB (54) No LOH No LOH 0.89 0.97 1.1 KvDMR: 0.50 
H19: 0.54
SDHB (55) No LOH No LOH 0.91 0.92 1.0
SDHB (56) No LOH No LOH 0.46 0.52 1.1
SDHB (57) No LOH No LOH 0.23 0.33 1.4
LOH: loss of heterozygosity. n.i : not informative
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confined to other chromosomes. Compared to SDHD and 
SDHAF2, SDHB tumors show a more complex pattern of 
chromosome 11 loss and characteristic changes affecting 
other chromosomes. Closer analysis to the allele ratios 
of various microsatellite markers in all tumors revealed 
a scattered segmental LOH pattern (Supplementary 
Table 5). While loss might be partly masked by tumor 
heterogeneity and copy neutral LOH, either of which 
could impair the detection of genomic alterations [23], the 
complex pattern of chromosome 11 loss we observed was 
specific to SDHB tumors. Nevertheless, 4 (31%) SDHB-
related tumors showed loss of maternal chromosome 11p, 
perhaps signifying a role for the same modifier genes 
that play such a prominent role in SDHD and SDHAF2 
tumors. A low frequency of chromosome 11 loss in SDHB-
related tumors is in agreement with previous reports 
[11, 15]. While a proportion of the greater heterogeneity 
of chromosomal gains and losses we observed in SDHB 
mutant tumors might simply be a byproduct of genomic 
instability, many changes are recurrent and thus apparently 
under the influence of selection, especially losses on 
chromosomes 1p, 3q, 11p, and 17p and somatic gain of 
chromosome 1q. One or more modifier genes on these 
autosomes may work in specific synergistic combinations 
to initiate or promote tumor growth. These recurring and 
often non-overlapping chromosomal changes also point to 
a potential redundancy in modifiers, and as such, altered 
expression of different groups of modifier genes might 
be involved in SDHB tumorigenesis. Analysis of a much 
larger number of SDHB tumors will be required to resolve 
this question. 
Interestingly, recent work [24, 25] showed that 
engineering in vitro the loss of chromosome 8p in cells 
alters fatty acid and ceramide metabolism. The shift in 
lipid metabolism triggered tumorigenic potential under 
stress conditions. Such a complex metabolic shift is 
difficult to ascribe to a dosage effect of a single gene, and is 
more likely the result of multiple genes on 8p coordinately 
undergoing a dosage change. This mechanism might also 
be at work in SDHx-related tumors, with chromosome 
11p loss necessary and sufficient to trigger SDHD and 
SDHAF2 tumorigenesis, whereas SDHB tumors require 
amplification or deletion of multiple driver genes located 
on different chromosomes. 
This speculation is supported by the striking 
difference in penetrance. A characteristic feature of SDHD 
and SDHAF2-related mutations is very high penetrance 
(90–100%) [8, 26], in contrast to SDHB mutations that 
Figure 3: SNP array results of SDHx and VHL-mutated paragangliomas/pheochromocytomas. Genomic frequency plots 
of gains (in blue) and deletions (in red) among 11 SDHD, 4 SDHAF2, 7 SDHB and 3 VHL-mutated tumors, obtained with Nexus Express. 
SDHD, SDHAF2 and VHL mutant paragangliomas/pheochromocytomas have the highest frequency of 11p loss, while the loss of 1p is a 
frequent event in SDHB mutant tumors. The X-axis shows the genomic position along the chromosomes and the Y-axis shows the frequency 
(%) of copy number gains and losses.
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have an estimated penetrance of only 20–30% [27–29]. 
This striking difference cannot be readily explained by 
functional differences between the respective proteins 
and therefore suggests a role for genetic effects, such as 
chromosomal location. In this scenario, tumorigenesis 
in SDHD and SDHAF2 mutation carriers requires only 
a single somatic genetic event (chromosome 11 loss), 
as opposed to the two or more independent somatic 
events required in SDHB mutation carriers (loss of the 
respective wild type allele, together with loss or gain of 
other chromosomal regions). In conclusion, our results 
clearly show that SDHB tumors follow a more complex 
and possibly different path to tumorigenesis compared to 
SDHD and SDHAF2-related PGLs, involving loss or gain 
of a greater proportion of the genome.
Despite the apparently integrated function of the 
SDH subunits, mutations in individual subunit genes result 
in a number of striking genetic, phenotypic and clinical 
differences.
Our data now highlight further differences 
between SDHB-related PGL/PCC compared to SDHD, 
SDHAF2 or VHL mutant PGL/PCC in terms of maternal 
chromosome 11 loss and additional genomic instability. 
Loss of maternal chromosome 11 is a highly specific 
and statistically significant event in the latter tumors, 
suggesting an important role for a still unidentified 
chromosome 11 factor in the genesis of paraganglioma. 
MATERIALS AND METHODS
Patients and samples
A total of 44 formalin-fixed, paraffin-embedded 
(FFPE) tissue samples of PGL/PCC from 41 different 
patients were used for DNA extraction, including 12 
SDHB, 16 SDHD, 9 SDHAF2 and 8 VHL-related tumors. 
In addition, we included 12 fresh frozen tumor samples for 
DNA extraction; 11 SDHD and 1 SDHB-mutated tumors. 
The histology of all tumors was reviewed (JVMGB, JPB, 
ASH) and the mutation detection was confirmed by routine 
SDHA and SDHB immunohistochemical staining, as 
described previously [30] (Supplementary Figure 1). For 
7 SDHAF2 mutant tumors and 4 SDHB mutant tumors, 
paired blood lymphocyte DNA samples were available. In 
addition, parental blood lymphocyte DNA was available 
for 3 SDHAF2-linked patients. Following the original 
identification of the SDHAF2 mutation, c.232G>A, 
p.Gly78Arg, all patients were analyzed by sequencing for 
the presence of the mutation [8]. The following primers 
were used for the amplification of exon 2 of the SDHAF2 
gene: 5′-GTTGACCTTCCCAGGCTC-3′ (forward) and 
5′-GAGGTTCAGCTGCTTTTCTG-3′ (reverse). Thirty 
nanograms of genomic DNA from each patient was 
amplified, and primer annealing was performed at 58°C. 
PCR fragments were purified using the Nucleospin gel 
and PCR clean-up kit (Macherey-Nagel). Sequencing 
was performed using standard protocols. Sequences were 
analyzed using the Mutation Surveyor software package 
(Softgenetics).
The SDHB-related samples were obtained 
from Radboud UMC, Nijmegen, The Netherlands, 
from UMCG, Groningen, The Netherlands and from 
University Hospital Southampton, UK. SDHD-related 
samples were obtained from the LUMC, Leiden, The 
Netherlands. SDHAF2-related samples were obtained 
from Radboud UMC and LUMC. VHL-related samples 
were obtained from the Erasmus MC, Rotterdam, The 
Netherlands. Written informed consent was obtained 
for DNA testing, further analyses and publication of all 
results, according to protocols approved by the Ethics 
Committees of the Erasmus MC, Radboud UMC, and 
University Hospital Southampton. Tissues from UMCG 
were used anonymously in accordance with the code 
for adequate secondary use of tissue, code of conduct: 
“Proper Secondary Use of Human Tissue” established 
by the Dutch Federation of Medical Scientific Societies 
(http://www.federa.org). Oral informed consent was 
obtained from patients according to protocols approved by 
the Ethics Committees of the LUMC, Protocol P12.082. 
Patients’ clinical and genetic data of the tumors included 
in our study is provided in Supplementary Table 1. 
Triple colour interphase FISH on nuclei isolated 
from paraffin-embedded tissue
The PUC1.77 probe for the centromeric alphoid 
repeat DNA of chromosomes 1 was kindly provided by 
Dr J Wiegant (Department of Molecular Cell Biology, 
LUMC, Leiden, The Netherlands) [31, 32]. The BAC 
probes 371C18 (telomere 11p) and 469N6 (telomere 
11q) were obtained from the Children’s Hospital Oakland 
Research Institute (Peter de Jong BAC library RP11). All 
probes were labelled by standard nick translation with 
biotin-16-aUTP, digoxigenin-11-dUTP or fluorescein-12-
dUTP (Roche, Basel, Switzerland). 
Isolation of intact nuclei, hybridization and 
immunodetection were performed as previously described 
[33], with some modifications. The hybridization mix 
contained 50% formamide, 3 ng/µl of each of the three 
probes (either PUC1.77, pLC11A and 3F7 or PUC1.77, 
371C18 and 469N6) and a 50-fold excess of human Cot-1 
DNA (Invitrogen Life tech., Paisley, UK). A volume of 5 µl 
of the mix was applied directly onto the slides and covered 
with an 18 × 18 mm2 coverslip. After a denaturation step 
of 8 min at 80°C, the slides were incubated overnight at 
37°C in a moisture chamber. A total of 200 nuclei were 
analysed for each sample and probe combination by two 
independent investigators (EFH and ESJ).
LOH analysis by microsatellite genotyping
Representative tumor areas from FFPE samples 
were selected to punch 3 cores of 0.6 mm in diameter 
for DNA isolation. Microdissection was performed on 8 
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SDHB-related tumors, using a total of two 10 μm thick 
sections for each case. A tumor percentage of greater than 
80% was achieved for all tumors. FFPE and fresh frozen 
tumor samples were incubated overnight with proteinase 
K at 60°C and DNA was isolated using the Qiagen FFPE 
DNA kit or QIAamp DNA Mini Kit (Qiagen Benelux 
B.V., Venlo, The Netherlands), respectively, according to 
the manufacturer’s instructions. Tumor and blood samples 
were genotyped for microsatellite markers located on 
chromosome 11, as described in the results section. Primer 
sequences of the microsatellite markers are described in 
Supplementary Table 7. For each marker, 40 ng of DNA 
was amplified over 40 cycles using FastStar Taq DNA 
Polymerase (Roche). Forward primers were labeled with 
6-FAM, HEX or NED fluorophore (Sigma-Aldrich, St. 
Louis, MO, USA). Amplicons of microsatellite markers 
were run on an ABI 3730 genetic analyzer and data were 
analyzed using Gene Marker software (Soft Genetics, State 
College, PA 16803, USA), using ABI GeneScan Rox 400 
as the internal size standards. LOH was calculated using the 
allelic imbalance ratio: AIR = (Tumor1/Tumor2)/(Normal1/
Normal2). Tumors were regarded as positive for LOH 
when the mean allele ratio between tumor and blood was < 
0.7 for all informative markers, as described earlier [34]. In 
cases where no matching blood lymphocyte DNA sample 
was available, allele peak ratios were compared to DNA 
samples with the same or very similar allele combinations. 
Some markers were either not informative in the patient 
or did not perform well enough on tumor DNA samples to 
give a reliable result and were therefore excluded.
Methylation analysis of H19-DMR and KvDMR
Bisulfite conversion of 250 ng of tumor DNA was 
performed with the EZ DNA Methylation Kit (Zymo 
Research, Irvine, CA, USA) according to the manufacturer’s 
instructions. Bisulfite treated DNA was amplified by PCR 
with primers specific for modified DNA, designed using 
Methprimer [35]. Primer sequences for the H19-DMR were 
5′-GGTTT TAGTGTGAAATTTTTTT-3′ (forward) and 
5′-CCATAAATATCCTATTCCCAAATAAC-3′ (reverse) and 
for the KvDMR 5′-TTGAGGAGTTTTTTGGAGGTT-3′ 
(forward) and 5′-ACCC AACCAATACCTCATAC-3′ 
(reverse). The PCR program consisted of an initial 
denaturation step at 94°C for 15 minutes followed by 44 
cycles of 20 seconds at 94°C, 30 seconds at 55°C for the 
KvDMR and 52.5°C for the H19-DMR, followed by 5 
minutes at 72°C. PCR fragments were purified using the 
Nucleospin gel and PCR clean-up kit (Macherey-Nagel, 
Düren, Germany). Sanger sequencing was performed using 
standard protocols and methylation rates were evaluated 
using ESME software [36].
Oncoscan analysis
Twelve SDHD, four SDHAF2, nine SDHB, and 
three VHL mutant tumors (Supplementary Table 1) were 
further investigated for whole genome copy number by 
OncoScan analysis (molecular inversion probe technology), 
as described in [37]. This array consists of ~335.000 probes 
of which the majority (~283.000) are SNP-based. DNA was 
processed by the Affymetrix Research Services Laboratory 
(Santa Clara, California, USA) using the OncoScan™ 
FFPE Assay. The normalized OncoScan data (2Log (test/
reference)-ratios and B-allele frequency plots) were analyzed 
with the Nexus Express software version 3.1 (Biodiscovery, 
Inc, El Segundo, California, USA) for copy number calling.
Statistical analysis
IBM SPSS Statistics 20.0 for Windows software 
package (SPSS, Armonk, NY: IBM Corp) was used to 
analyze the results. Statistical significance between two 
groups was determined by Mann-Whitney U test. P < 0.05 
was considered statistically significant.
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